JP2024512767A5 - - Google Patents
Info
- Publication number
- JP2024512767A5 JP2024512767A5 JP2023560831A JP2023560831A JP2024512767A5 JP 2024512767 A5 JP2024512767 A5 JP 2024512767A5 JP 2023560831 A JP2023560831 A JP 2023560831A JP 2023560831 A JP2023560831 A JP 2023560831A JP 2024512767 A5 JP2024512767 A5 JP 2024512767A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- membered
- alkyl
- hydrogen
- bonded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170292P | 2021-04-02 | 2021-04-02 | |
| US63/170,292 | 2021-04-02 | ||
| US202163192843P | 2021-05-25 | 2021-05-25 | |
| US63/192,843 | 2021-05-25 | ||
| PCT/US2022/023133 WO2022212894A1 (en) | 2021-04-02 | 2022-04-01 | Methods for inhibiting ras |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024512767A JP2024512767A (ja) | 2024-03-19 |
| JP2024512767A5 true JP2024512767A5 (https=) | 2025-04-08 |
Family
ID=83456876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560831A Pending JP2024512767A (ja) | 2021-04-02 | 2022-04-01 | Ｒａｓの阻害方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240108630A1 (https=) |
| EP (1) | EP4320143A4 (https=) |
| JP (1) | JP2024512767A (https=) |
| KR (1) | KR20240004436A (https=) |
| AU (1) | AU2022249177A1 (https=) |
| BR (1) | BR112023020182A2 (https=) |
| CA (1) | CA3214155A1 (https=) |
| CR (1) | CR20230500A (https=) |
| IL (1) | IL307396A (https=) |
| MX (1) | MX2023011608A (https=) |
| TW (1) | TW202308632A (https=) |
| WO (1) | WO2022212894A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023199180A1 (en) * | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| JP2025519199A (ja) * | 2022-06-01 | 2025-06-24 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のためのハロインドール大環状化合物 |
| EP4582426A4 (en) * | 2022-09-19 | 2025-12-24 | Adlai Nortye Biopharma Co Ltd | PAN-KRAS INHIBITOR COMPOUND |
| KR20250085767A (ko) | 2022-09-29 | 2025-06-12 | 광조우 조요 파마테크 컴퍼니 리미티드 | 거대고리 유도체 및 이의 적용 |
| CN118047797A (zh) * | 2022-11-16 | 2024-05-17 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| CN117534684A (zh) * | 2022-11-29 | 2024-02-09 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| WO2024167880A1 (en) * | 2023-02-06 | 2024-08-15 | Bicara Therapeutics Inc. | Combination therapy and related methods |
| CN120813588A (zh) | 2023-02-14 | 2025-10-17 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的三环化合物 |
| WO2024187174A2 (en) * | 2023-03-09 | 2024-09-12 | Aadigen, Llc | Compositions for treating cancer with kras mutations and uses thereof |
| AU2024241633A1 (en) * | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025051241A1 (zh) * | 2023-09-06 | 2025-03-13 | 劲方医药科技(上海)股份有限公司 | 大环化合物及其抗体-药物偶联物 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025087431A1 (zh) * | 2023-10-27 | 2025-05-01 | 贝达药业股份有限公司 | 泛-kras抑制剂及其在医药上的应用 |
| WO2025093625A1 (en) * | 2023-11-01 | 2025-05-08 | F. Hoffmann-La Roche Ag | Macrocycle compounds for the treatment of cancer |
| WO2025119392A1 (zh) * | 2023-12-08 | 2025-06-12 | 正大天晴药业集团股份有限公司 | 含有酰胺取代的大环类化合物 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025193628A2 (en) * | 2024-03-09 | 2025-09-18 | Aadigen, Llc | Compositions for treating cancer with kras mutations and uses thereof |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025252241A1 (zh) * | 2024-06-07 | 2025-12-11 | 杭州和正医药有限公司 | 一种大环衍生物及其用途 |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015745A1 (en) * | 2024-07-11 | 2026-01-15 | Treeline Biosciences, Inc. | Macrocyclic ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101602876B1 (ko) * | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| BR112021012057A2 (pt) * | 2018-12-21 | 2021-10-19 | Revolution Medicines, Inc. | Compostos que participam de ligação cooperativa e usos dos mesmos |
| CA3194067A1 (en) * | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
-
2022
- 2022-04-01 MX MX2023011608A patent/MX2023011608A/es unknown
- 2022-04-01 WO PCT/US2022/023133 patent/WO2022212894A1/en not_active Ceased
- 2022-04-01 CR CR20230500A patent/CR20230500A/es unknown
- 2022-04-01 EP EP22782324.2A patent/EP4320143A4/en active Pending
- 2022-04-01 KR KR1020237037749A patent/KR20240004436A/ko active Pending
- 2022-04-01 IL IL307396A patent/IL307396A/en unknown
- 2022-04-01 JP JP2023560831A patent/JP2024512767A/ja active Pending
- 2022-04-01 BR BR112023020182A patent/BR112023020182A2/pt unknown
- 2022-04-01 TW TW111112802A patent/TW202308632A/zh unknown
- 2022-04-01 AU AU2022249177A patent/AU2022249177A1/en active Pending
- 2022-04-01 CA CA3214155A patent/CA3214155A1/en active Pending
-
2023
- 2023-10-02 US US18/479,500 patent/US20240108630A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024512767A5 (https=) | ||
| JP2024521774A5 (https=) | ||
| CN110003204B (zh) | 一种bet蛋白抑制剂、其制备方法及用途 | |
| JP2026041825A (ja) | 固体形態 | |
| Chiyanzu et al. | Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives | |
| DK2152692T3 (en) | EXTERNAL anti-cancer activity | |
| ES2387270T3 (es) | El archivo contiene la información técnica propuesta después de la presentación de la solicitud y no se incluye en esta especificación | |
| DK2924034T3 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | |
| JP2024521920A5 (https=) | ||
| Patel et al. | Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle | |
| JP7274765B2 (ja) | フェニルトリアゾールｍｌｌ１－ｗｄｒ５タンパク質間相互作用阻害剤 | |
| JP2018530594A (ja) | 新規な化合物であるｙａｐ／ｔａｚ−ｔｅａｄ相互作用阻害剤、および悪性中皮腫の治療でのその使用 | |
| WO2017167182A1 (zh) | 一种选择性的c-kit激酶抑制剂 | |
| JP2010512358A (ja) | スルホンアミドならびに薬剤としてのその使用 | |
| CN105579449A (zh) | 新的用作nampt抑制剂的吡啶基氧基乙酰基四氢异喹啉化合物 | |
| CN108101890A (zh) | N-磺酰基吡咯衍生物 | |
| TW200301698A (en) | Acridone inhibitors of IMPDH enzyme | |
| KR20070112400A (ko) | 신규의 ｈｓｐ90 저해제 | |
| TW200815342A (en) | Novel sulphonylpyrroles | |
| JP2012512887A5 (https=) | ||
| Ghomashi et al. | Recent advances in biological active sulfonamide based hybrid compounds part A: Two-component sulfonamide hybrids | |
| CN106795150A (zh) | 1,3,4‑噻二唑化合物及其在治疗癌症中的用途 | |
| CN119528810A (zh) | 喹啉类化合物及其应用 | |
| TW200812970A (en) | Inhibitors of AKT (protein kinase B) | |
| TW200927127A (en) | Agent for overcoming resistance to anti-cancer agent |